Compare MUX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | NUVB |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | Canada | United States |
| Employees | 1432 | 291 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | MUX | NUVB |
|---|---|---|
| Price | $21.39 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $26.63 | $11.38 |
| AVG Volume (30 Days) | 988.1K | ★ 4.5M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.52 | $190.15 |
| Revenue Next Year | $26.24 | $62.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.38 | $1.57 |
| 52 Week High | $29.70 | $9.75 |
| Indicator | MUX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 45.66 |
| Support Level | $17.91 | $4.07 |
| Resistance Level | $26.94 | $5.55 |
| Average True Range (ATR) | 1.23 | 0.22 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 52.12 | 77.78 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.